SEC Form 4 · accession 0001193125-26-390509
Amylyx Pharmaceuticals, Inc. · AMLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M Frates
Officer — Chief Financial Officer
Period of report
Sep 10, 2026
Accepted (ET)
Sep 14, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 10, 2026 | S | 9,768 | $32.2681 | D | 234,667 | D | |
| Common StockF3 | Sep 10, 2026 | S | 1,042 | $33.2302 | D | 233,625 | D | |
| Common StockF4 | holding | — | — | — | 100,000 | I | By Trust | |
| Common StockF5 | holding | — | — | — | 15,459 | I | By Trust | |
| Common StockF6 | holding | — | — | — | 11,072 | I | By Trust | |
| Common StockF7 | holding | — | — | — | 40,000 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805 to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F4Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F5Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F6Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F7Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.